Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)

Trial Profile

Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Tenofovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms PAS
  • Most Recent Events

    • 09 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2018.
    • 09 Aug 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2018.
    • 12 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top